A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Table 2 Results of Kaplan–Meier and ROC analysis based on different regrouping methods

Regrouping factors	Group	Sample size	Kaplan–Meier, P value	AUC	95% CI of AUC
Age at diagnosis	≤ 50	127	1.32E−02	0.680	0.56–0.80
	51–60	178	9.40E−05	0.774	0.69–0.86
	> 60	246	1.17E−04	0.720	0.65–0.79
FIGO stage	I and II	42	6.76E−02	0.778	0.59–0.96
FIGO stage	III and IV	505	1.03E−09	0.735	0.69–0.79
Histologic grade	G2	69	2.91E−02	0.696	0.53–0.86
Histologic grade	G3	478	3.26E−09	0.740	0.69–0.79
Anatomic subdivision	Unilateral	140	4.27E−04	0.753	0.66–0.85
Anatomic subdivision	Bilateral	383	4.73E−07	0.727	0.67–0.79
Tumor residual disease (mm)	No macroscopic disease	116	1.17E−03	0.795	0.67–0.92
	1–10	255	1.16E−03	0.665	0.59–0.76
	> 10	138	5.18E−05	0.770	0.68–0.86

ISSN: 1868-7083